US Stock MarketDetailed Quotes

AMGN Amgen

Watchlist

291.160
-3.430-1.16%

Close Feb 14 16:00 ET

291.250
+0.090+0.03%

Post 20:01 ET

156.41BMarket Cap38.51P/E (TTM)

Amgen Stock Forum

Tao Lao Man Official

Feb 12 15:16

$Amgen (AMGN.US)$
AMGN, MRNA, PFE, JNJ ARE SAME BUS OR NOT = AMGN, MRNA, PFE, JNJ SEM BUT ZAY KO 🤔

Moomoo News Global

Feb 5 07:04

Columns Tariff Investment Opportunities: Four Sectors as Potential Safe Havens

Over the weekend, President Donald Trump announced tariffs on the U.S.'s top three trading partners—Canada, Mexico, and China—and threatened similar measures against the EU. On Monday, U.S. stocks experienced a selloff, with the major indices dropping. Losses narrowed, however, after news broke of a delay in imposing tariffs on Mexico.
Market worries over the tariffs focus on two key issues. U.S. companies that depend heavily ...

Stock_Drift

Feb 4 15:42

Amgen Q4 revenue up 11%, at $9.1B

$Amgen (AMGN.US)$

10xStockPicks

Jan 23 07:47

Today 3 Analysts Place BUY Ratings On This $2 Stock $7,$9 & $16 Which Is An Acquisition Target by BIG Pharma

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...

Stock_Drift

Jan 18 08:51

$GlaxoSmithKline (GSK.US)$ $Amgen (AMGN.US)$ $AstraZeneca (AZN.US)$

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

vampirekitty169

Dec 31, 2024 09:05

🚀🚀🚀

$Amgen (AMGN.US)$ Bought as soon as I got the news and it’s +3% within 10 minutes, looking good!

What's new: Latest stock news and analysis

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14, 2024 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

Mr Long Term

Dec 12, 2024 18:17

Columns These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over.

It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare underperformed.
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...